Novavax terminates Estrasorb agreement with Allergan

ROCKVILLE, Md. Novavax has terminated its manufacturing supply agreement with Allergan for the drug Estrasorb, which is used to treat hot flashes that are associated with menopause.

The drug was licensed by Novavax to Esprit Pharma, which was recently acquired by Allergan. Novavax will manufacture remaining orders before closing its facility and Allergan will sell the drug from available inventory.

Novavax will now look to focus on its vaccine business. The company also announced that it regained the rights from Allergan to develop ESP 210, a drug in Phase II development for hypoactive sexual desire disorder.